BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Utidelone readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Utidelone\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06683703-2272@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Utidelone: Phase 2 readout est. (NCT06683703)
DESCRIPTION:Utidelone\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Utide
 lone Injection Combined with Bevacizumab Injection for Non-small Cell Lung
  Cancer Patients with Brain Metastases\nEstimated primary completion: 1 De
 cember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/utidelon
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 683703
URL:https://assetmemo.bio/drug/utidelone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05398861-2272@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Utidelone: Phase 2 readout est. (NCT05398861)
DESCRIPTION:Utidelone\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of 
 HER-2 Negative Advanced Breast Cancer\nEstimated primary completion: 30 De
 cember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/utidelon
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 398861
URL:https://assetmemo.bio/drug/utidelone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06730581-2272@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Utidelone: Phase 2 readout est. (NCT06730581)
DESCRIPTION:Utidelone\, phase 2.\nStudy: Utidelone Capsule Monotherapy for 
 Patients with Advanced Solid Tumors\nEstimated primary completion: 31 Dece
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/utidelone#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0673
 0581
URL:https://assetmemo.bio/drug/utidelone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06764940-2272@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Utidelone: Phase 2 readout est. (NCT06764940)
DESCRIPTION:Utidelone\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitab
 ine in HER2-negative Breast Cancer Patients With Brain Metastases\nEstimat
 ed primary completion: 15 January 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/utidelone#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06764940
URL:https://assetmemo.bio/drug/utidelone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07044349-2272@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Utidelone: Phase 2 readout est. (NCT07044349)
DESCRIPTION:Utidelone\, phase 2.\nStudy: Phase II Clinical Study of Utidelo
 ne Capsule (UTD2) in Patients With Advanced Epithelial Ovarian\, Fallopian
  Tube\, or Primary Peritoneal Cancer\nEstimated primary completion: March 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/utidelone#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07044349
URL:https://assetmemo.bio/drug/utidelone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05172518-2272@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Utidelone: Phase 3 readout est. (NCT05172518)
DESCRIPTION:Utidelone\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-neg
 ative Locally Advanced or Metastatic Breast Cancer\nEstimated primary comp
 letion: 1 March 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /utidelone#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05172518
URL:https://assetmemo.bio/drug/utidelone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06510465-2272@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Utidelone: Phase 2 readout est. (NCT06510465)
DESCRIPTION:Utidelone\, phase 2.\nStudy: Neoadjuvant Therapy With Weekly Ut
 idelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA
 )\nEstimated primary completion: 31 March 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/utidelone#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06510465
URL:https://assetmemo.bio/drug/utidelone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06973421-2272@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Utidelone: Phase 2 readout est. (NCT06973421)
DESCRIPTION:Utidelone\, phase 2.\nStudy: Phase II Study of Utidelone Plus F
 ruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian C
 ancer\nEstimated primary completion: 30 June 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/utidelone#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06973421
URL:https://assetmemo.bio/drug/utidelone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07363330-2272@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Utidelone: Phase 2 readout est. (NCT07363330)
DESCRIPTION:Utidelone\, phase 2.\nStudy: A Phase II Study of Utidelone With
  Toripalimab in Advanced Cervical Cancer\nEstimated primary completion: 31
  December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/utide
 lone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07363330
URL:https://assetmemo.bio/drug/utidelone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684456-2272@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Utidelone: Phase 3 readout est. (NCT07684456)
DESCRIPTION:Utidelone\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Efficacy and Safety of Utidelone Capsule and Utidelone Injection in Pat
 ients With HER-2 Negative Advanced Breast Cancer\nEstimated primary comple
 tion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/u
 tidelone#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07684456
URL:https://assetmemo.bio/drug/utidelone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06598046-2272@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Utidelone: Phase 2 readout est. (NCT06598046)
DESCRIPTION:Utidelone\, phase 2.\nStudy: A Single-arm\, Prospective Phase 
 Ⅱ Clinical Study of Utidelone Combined With Capecitabine in the Treatmen
 t of Active Brain Metastasis of TNBC\nEstimated primary completion: 1 June
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/utidelone#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06598046
URL:https://assetmemo.bio/drug/utidelone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07021261-2272@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20300616
DTEND;VALUE=DATE:20300617
SUMMARY:Utidelone: Phase 3 readout est. (NCT07021261)
DESCRIPTION:Utidelone\, phase 3.\nStudy: Comparing UTD2 Combined With Capec
 itabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients\nEst
 imated primary completion: 16 June 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/utidelone#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07021261
URL:https://assetmemo.bio/drug/utidelone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06841679-2272@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20300901
DTEND;VALUE=DATE:20300902
SUMMARY:Utidelone: Phase 2/3 readout est. (NCT06841679)
DESCRIPTION:Utidelone\, phase 2/3.\nStudy: Utidelone Capsule Combined With 
 Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment 
 of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma\nEsti
 mated primary completion: 1 September 2030. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/utidelone#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06841679
URL:https://assetmemo.bio/drug/utidelone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
